Although a patient's first instinct upon a breast cancer diagnosis, according to Tolaney, may be to remove it (understandably so), this may not always be the best course of action ... Essentially, ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

These results from patients with relapsed anal cancer support PELA’s immunologic mechanism of action as previously ... An antibody-drug conjugate like Enhertu. However, some patients may not ...

IQVIA also found there were 50 other mechanisms of action being evaluated in the clinic, with 43% being oral therapies, 55% parenteral therapies, and 2% administered in another way. 3 Big news is ...

The company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu ...

Given its novel mechanism of action and proven efficacy ... Tukysa improving survival for HER2+ brain metastases, plus Enhertu and other antibody-drug conjugates, and new targeted therapies ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in the ...